PPD, Inc. (Nasdaq: PPDI) has added another office to its operations in Russia, bringing to four the number of its locations there.

The latest office is in Novosibirsk. It is part of Phase II-IV clinical-development services that PPD offers in Eastern Europe. The Novosibirsk office will provide clinical monitoring services in key therapeutic areas, PPD said in announcing the opening Thursday.

PPD’s other Russian offices are in Moscow, Smolensk and St. Petersburg. PPD is one of the largest CROs operating in Central and Eastern Europe, which the company said it sees as an important, high-growth market for clinical trials because they offer efficient access to patients and a well-developed, centralized health care system.

"Establishing a presence in Novosibirsk allows us to serve clients more effectively and keep pace with clinical trial growth in this region,” said Roger Newbery, vice president of clinical development for Europe, Middle East and Africa. “This expansion provides us the ability to reach more than five million people and grow our number of investigator sites to meet growing client demand.”

Get the latest news alerts: at Twitter.